COVID-19 drug practices risk antimicrobial resistance evolution

Authors

Ebrahim Afshinnekoo, Weill Cornell Medicine
Chandrima Bhattacharya, Weill Cornell Medicine
Ana Burguete-García, Instituto Nacional de Salud Pública. México
Eduardo Castro-Nallar, Universidad Andrés Bello
Youping Deng, John A. Burns School of Medicine
Christelle Desnues, Aix Marseille Université
Emmanuel Dias-Neto, Universidade de São Paulo
Eran Elhaik, Lunds Universitet
Gregorio Iraola, Institut Pasteur de Montevideo
Soojin Jang, Institut Pasteur Korea
Paweł P. Łabaj, Uniwersytet Jagielloński
Christopher E. Mason, Weill Cornell Medicine
Niranjan Nagarajan, NUS Yong Loo Lin School of Medicine
Michael Poulsen, Københavns Universitet
Bharath Prithiviraj, Brooklyn College
Rania Siam, University of Medicine and Health Sciences
Tieliu Shi, East China Normal University
Haruo Suzuki, Keio University
Johannes Werner, Eberhard Karls Universität Tübingen
Maria Mercedes Zambrano, Universidad Central, Bogota
Malay Bhattacharyya, Indian Statistical Institute, Kolkata

Find in your Library

https://doi.org/10.1016/S2666-5247(21)00039-2

Document Type

Research Article

Publication Title

The Lancet Microbe

Publication Date

4-1-2021

doi

10.1016/S2666-5247(21)00039-2

First Page

e135

Last Page

e136

Recommended Citation

APA Citation

Afshinnekoo, E. Bhattacharya, C. Burguete-García, A. Castro-Nallar, E. ... (2021). COVID-19 drug practices risk antimicrobial resistance evolution. The Lancet Microbe, 2(4), e135–e136. 10.1016/S2666-5247(21)00039-2
https://fount.aucegypt.edu/faculty_journal_articles/2415

MLA Citation

Afshinnekoo, Ebrahim, et al. "COVID-19 drug practices risk antimicrobial resistance evolution." The Lancet Microbe, vol. 2,no. 4, 2021, pp. e135–e136.
https://fount.aucegypt.edu/faculty_journal_articles/2415